Trial reportBMC anesthesiology2025
Effects of ultrasound-guided transversus abdominis plane block with combined dexmedetomidine and dexamethasone on the stress and immune function.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundUltrasound-guided transversus abdominis plane (TAP) block is widely used to provide effective postoperative analgesia and facilitate enhanced recovery after laparoscopic radical colectomy. However, the duration of TAP block is often limited by the pharmacokinetics of local anesthetics, and evidence regarding optimal adjuvant combinations to prolong its efficacy remains scarce.
methodsIn this prospective, randomized controlled trial, 160 patients undergoing elective laparoscopic colectomy were randomly assigned to four groups (n = 40 each): Control (ropivacaine alone), Dexmedetomidine group (ropivacaine + dexmedetomidine), Dexamethasone group (ropivacaine + dexamethasone), and Combination group (ropivacaine + dexmedetomidine + dexamethasone). Primary outcomes included postoperative pain scores and sufentanil consumption. Secondary outcomes included Ramsay Sedation Scores, CD4+/CD8 + T cell ratios, and serum markers of stress response.
resultsCompared to ropivacaine alone, both dexmedetomidine and dexamethasone as single adjuvants significantly reduced postoperative pain scores and opioid requirements (p < 0.05). The combination group exhibited the most prolonged analgesic effect, with significantly lower sufentanil consumption and higher sedation scores at 6 and 24 h (p < 0.01). Moreover, both adjuvants attenuated the postoperative decline in CD4+/CD8 + T cell ratio, and the combination group demonstrated the greatest preservation of immune function and suppression of stress-induced immunosuppression.
conclusionsThe combination of dexmedetomidine and dexamethasone as adjuvants to ropivacaine in TAP block provides superior and prolonged analgesia, reduces opioid consumption, and offers additional immunomodulatory benefits. This strategy represents a promising enhancement to multimodal analgesia protocols for patients undergoing laparoscopic colectomy.
trial registrationThe study was registered in Chinese Clinical Trial Registry (ChiCTR2200065816, 2022-11-16).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.